News

From “all-in-one” healthcare appointments to coordinating women’s care for convenience, here’s how providers and researchers say plans and providers can prioritize

The AMA and medical schools across the country are placing new emphasis on population health management and value-based care.

Experts share how Trump could change Obamacare coverage, accessibility, affordability, Medicare/Medicaid, price transparency, and more.

Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.

Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.

Leader of the YMCA’s Diabetes Prevention Program explains how it is improving diabetes care.

The Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness.

As fee-for-service rapidly transforms into value-based care, the industry must improve member engagement and outcomes by using targeted care management interventions that help deliver bottom-line results across a broader spectrum of the population.

The path to bundled payment success can be daunting. Here’s three universal concepts that will promote success under the various CMS models.

Retail clinics emerge as a way to satisfy the growing demand for healthcare created by the newly insured under the ACA, but contrary to expectations, they do not appear to be leading to meaningful reductions in low-acuity ED visits.

Understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients.

Following the GOP’s success on Election Day, the nation is quickly tuning in to what this all means for healthcare coverage.

CMS announced changes to how Medicare pays for primary care. Here’s 5 things to consider.

: Remembering to engage in healthy behavior can often slip to the bottom of our list of priorities. In a world where we need to be reminded and motivated to be the healthiest version of ourselves, the right nudges at the right time can help us get there.

A global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.

After a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017.

Humana’s value-based reimbursement model with physicians has helped to improve care quality and health outcomes for its Medicare Advantage (MA) program members.

Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results.

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.

By addressing the root problem of obesity with structured programs, providers can help patients lose weight and very possibly avoid expensive chronic illnesses as a result. Employers and payers should incentivize healthy weight by paying for obesity care and treatment, potentially reaping substantial savings in the long term.

Creating a comprehensive customer experience doesn’t happen overnight, but the key to achieving it comes from taking a “bone deep” approach.

Many aspects of the ACA have been assimilated into the healthcare system. Will a Trump administration undo them?

The results of Geneia’s year-long study – a savings of $8,375 per patient and a slowing of disease progression – demonstrate that remote patient monitoring is a wise investment for payers.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

A new Express Scripts report highlights risk reporting gaps and offers advice for plans looking to close those gaps to ensure accurate risk payments

Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.

After Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments.

FDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.